Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer

In brief

RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with advanced non-small cell lung cancer.

Key facts

Study ID

NCT00416650

Run by

Vanderbilt-Ingram Cancer Center

People needed

16

Starts

2002-07-01

Expected to finish

2013-03-01

Last updated by the study team

2013-04-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Northwestern Memorial Hospital — Chicago, Illinois, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.